Cholesterol

1 in 25 carries a genotype that is associated with a shortened lifespan

Retrieved on: 
Wednesday, November 15, 2023
Icelanders, ACMG, Disclosure, Genetics, Breast, Gene, Genetic distance, Proteomics, Risk, Disease, Cholesterol, Cardiovascular disease, Paper, DSM-IV codes, Icelandic, Medicine, Prostate cancer, American College, Genome, Genotype, Survival, Medical genetics, Government, AMGN, Vaccine, Pharmaceutical industry, Genomics, LDLR, Amgen

REYKJAVIK, Iceland, Nov. 8, 2023 /PRNewswire/ -- The study, published today in the New England Journal of Medicine, focuses on genotypes that increase the risk of a disease for which preventive or therapeutic measures have been established. These genotypes are termed actionable genotypes. The scientists used a population-based data set, consisting of 58,000 whole-genome sequenced Icelanders, to assess the fraction of individuals carrying actionable genotypes.

Key Points: 
  • The scientists used a population-based data set, consisting of 58,000 whole-genome sequenced Icelanders, to assess the fraction of individuals carrying actionable genotypes.
  • The study assessed the relationship between actionable genotypes and the lifespan of their carriers.
  • A pathogenic variant in BRCA2, predisposing to breast, ovarian and pancreatic cancer, shortened lifespan by seven years and a variant in LDLR, which causes high levels of cholesterol and cardiovascular disease, shortened lifespan by six years.
  • The researchers determined that 1 in 25 individuals carried an actionable genotype and have, on average, a shortened lifespan.

AMGEN PRESENTS NEW CARDIOVASCULAR RESEARCH AT AHA 2023

Retrieved on: 
Friday, November 10, 2023
Massachusetts General Hospital, Moyamoya disease, Research, Safety, Lipoprotein(a), Deficit spending, Consortium, Risk, AHA, Cholesterol, Hospital, Cardiovascular disease, Patient, Small RNA, OLE, LDL, Function (mathematics), MACE, American Heart Association, Stroke, Harvard Medical School, RNA, CVD, Splenic infarction, ASCVD, Dementia, Cardiology, Cone Health Women's Hospital, AMGN, Pharmaceutical industry, Evolocumab, Brigham, OCEAN, Amgen

THOUSAND OAKS, Calif., Nov. 10, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data reinforcing the safety and efficacy of Repatha® (evolocumab) from the FOURIER Open Label Extension (OLE) [FOURIER-OLE] trial at the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia. These presentations will focus on the reduction of a known cardiovascular disease (CVD) risk factor, LDL "bad" cholesterol (LDL-C). Amgen will also present new research from the Phase 2 OCEAN(a)-DOSE study of its investigational small interfering RNA (siRNA) olpasiran that will focus on a primarily genetically determined and presumed independent CVD risk factor, lipoprotein(a) [Lp(a)].1,2,3,4,5

Key Points: 
  • These presentations will focus on the reduction of a known cardiovascular disease (CVD) risk factor, LDL "bad" cholesterol (LDL-C).
  • Amgen also shared new research from the OCEAN(a)-DOSE study on Lp(a) involving its investigational olpasiran.
  • Additional research presented at AHA will include Mass General Brigham Lp(a) registry data on whether the association between Lp(a) and major adverse cardiovascular events (MACE) differs based on baseline ASCVD status.
  • Amgen will reconvene the LDL-C Action Summit and the newly formed LDL Awareness to Action Implementation Consortium ahead of AHA.

Impossible Foods' Beef Lite1 Now Certified by American Heart Association Heart-Check Food Certification Program

Retrieved on: 
Thursday, November 9, 2023
General Health, Agriculture, Food, Beverage, Natural Resources, Environment, Fitness & Nutrition, Retail, Science, Cardiology, Climate Change, Other Science, Health, Taste, American Heart Association, Stroke, Sodium, Water, Beef, Impossible, Impossible Foods, Certification, Meat, Cholesterol, Reference Daily Intake, Multimedia, American Heart, Risk, Plant, Zinc, Coconut oil, Love, Noise, Potassium, Cardiovascular disease, Dietary supplement

Today, Impossible Foods’ protein-packed Impossible™ Beef Lite received certification from the American Heart Association’s Heart-Check Food Certification Program .

Key Points: 
  • Today, Impossible Foods’ protein-packed Impossible™ Beef Lite received certification from the American Heart Association’s Heart-Check Food Certification Program .
  • Following a rigorous review process, Beef Lite is now among a cohort of products that meet the American Heart Association’s robust, science-based nutrition criteria for heart-healthy2 foods.
  • View the full release here: https://www.businesswire.com/news/home/20231106736997/en/
    Impossible™ Beef Lite is now among a cohort of products that meet the American Heart Association’s robust, science-based nutrition criteria for heart-healthy foods.
  • “Earning this certification from the American Heart Association is a really important milestone for both Impossible Foods and the rest of the plant-based meat category,” said Peter McGuinness, CEO and President at Impossible Foods.

FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems

Retrieved on: 
Wednesday, November 8, 2023
Stroke, FDA, Eli Lilly and Company, Research, Physiology, Lilly, Constipation, Abdominal pain, Excipient, Insurance, United Kingdom, NYSE, Food, Hair loss, Health, BMI, Obesity, Government, Vomiting, GIP, Hope, Weight loss, Diarrhea, Blood pressure, LLY, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Diabetes, Tirzepatide, Cholesterol, News, Esophagitis, Exercise, Gastroparesis, Nausea, Pancreatitis, Type, Conditional sentence, Burping, Disease, Clinical trial, Thyroid cancer, Hypertension, Medication, Pharmacy, Diet, Indigestion, Overweight, Hunger, Gastrointestinal disease, Patient, Dyslipidemia, Obstructive sleep apnea, Hypersensitivity, Human, Cardiovascular disease, Fatigue, Pharmaceutical industry, Copper, Dietary supplement, Health insurance, Telescopic sight

INDIANAPOLIS, Nov. 8, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight (with a BMI of 27 kg/m2 or greater) and also have weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease, to lose weight and keep it off. It should be used with a reduced-calorie diet and increased physical activity. Zepbound should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines, and it has not been studied in patients with a history of pancreatitis, or with severe gastrointestinal disease, including severe gastroparesis.

Key Points: 
  • "Obesity is a chronic disease that can result in serious health complications, including heart disease, stroke and diabetes.
  • Despite our knowledge of obesity as a treatable, chronic disease, people living with obesity still face many challenges in their health and weight management journey," said Joe Nadglowski, president and chief executive officer of the Obesity Action Coalition.
  • "New treatment options bring hope to the many people with obesity who struggle with this disease and are seeking better options for weight management."
  • Tirzepatide is also under regulatory review for weight management in Europe, China, the United Kingdom and several additional markets.

23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership

Retrieved on: 
Tuesday, November 7, 2023
Knowledge, FDA, Medical genetics, American College, 23andMe, DPYD, Genetic testing, ACMG, Polygene, Biomarker, Health, Ovarian cancer, Therapy, Life, BRCA1, Reading, Genetics, Citalopram, Liver, Kidney, Research, Prostate cancer, Clinical Pharmacogenetics Implementation Consortium, Pharmacogenomics, Metabolism, Genomic Health, BRCA2, Genome, Heredity, Disease, LDL, CYP2C19, Risk, Asthma, Risk assessment, Cancer, Breast cancer, Saliva, Pancreatic cancer, PGS, Fetus, Gene, SLCO1B1, Anxiety, Breast, American College of Medical Genetics and Genomics, Lijun International Pharmaceutical (Holding) Co. Ltd., Cholesterol, SAN, DNA, Pharmaceutical industry, Medical imaging, Vaccine, Medical device, Dietary supplement

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched 23andMe+ Total Health, its new, comprehensive prevention-based health membership that provides clinical grade exome sequencing, biannual blood testing, and unprecedented access to genetics-based clinical care.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched 23andMe+ Total Health, its new, comprehensive prevention-based health membership that provides clinical grade exome sequencing, biannual blood testing, and unprecedented access to genetics-based clinical care.
  • Members of Total Health will also receive all the reports and features offered in the Company’s existing 23andMe+ Premium Membership .
  • As part of Total Health, members will gain access to all the premium reports and features delivered through 23andMe+ Premium.
  • The 23andMe+ Total Health membership will cost $99 per month, billed in a one-time annual payment of $1,188.

Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer

Retrieved on: 
Tuesday, November 7, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Neoplasm, Abdominal pain, Constipation, SOC, Headache, Food, Progression-free survival, European Commission, Vomiting, Diarrhea, Prevalence, PFS, Safety, DSM-IV codes, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HIV disease progression rates, Holding, Nausea, Multimedia, Civil service commission, ESR1, Risk, Triglyceride, MBC, ER, Breast cancer, Anemia, Woman, Indigestion, Cancer, Therapy, Arthralgia, Patient, Creatinine, Potassium, Death, Back pain, Cholesterol, Fatigue, Pharmaceutical industry

Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, commercializes ORSERDU in the U.S. and E.U.

Key Points: 
  • Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, commercializes ORSERDU in the U.S. and E.U.
  • Under the Sub-Licensing agreement, SciClone will pursue the development and registration of ORSERDU in China and commercialize ORSERDU upon its regulatory approval in China.
  • “Patients living with metastatic breast cancer need effective and tolerable options,” said Elcin Barker Ergun, CEO of the Menarini Group.
  • The primary endpoints of the study were PFS in the overall patient population and in patients with ESR1 mutations.

Global Self Testing Market Report 2023: Industry Size, Share, Trends, Opportunities, and Forecasts, 2018-2028F - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 7, 2023
Medical Supplies, Health, Diabetes, Telemedicine, Virtual Medicine, Genetics, General Health, Pharmaceutical, Fertility, Genetic testing, Alzheimer's disease, Insurance, Blood pressure, Prevalence, Conditional sentence, International Diabetes Federation, Market, MyHeritage, Growth, Risk, Telehealth, Parkinson's disease, Hospital, Ovulation, Breast cancer, Woman, Ancestry.com, Patient, Blood, Cholesterol, Competition, DNA, Retail, Online shopping, Pharmaceutical industry, Birth control, Medical device, Vaccine

One of the primary factors driving the growth of the global self-testing market is the convenience and accessibility that these products offer.

Key Points: 
  • One of the primary factors driving the growth of the global self-testing market is the convenience and accessibility that these products offer.
  • Global self-testing market has grown over the last few years due to the personalization that these products offer.
  • This, in turn, is expected to increase the demand for blood glucose testing and cholesterol testing segment of global self-testing market.
  • Company Profiles: Detailed analysis of the major companies present in Global Self Testing Market.

Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer

Retrieved on: 
Tuesday, November 7, 2023
Neoplasm, Patient, Abdominal pain, Constipation, SOC, Headache, Food, Progression-free survival, Fatigue, European Commission, Vomiting, Diarrhea, PFS, Safety, DSM-IV codes, HIV disease progression rates, Holding, Nausea, Republic, Civil service commission, ESR1, Risk, Triglyceride, MBC, ER, Breast cancer, Anemia, Woman, Oncology, Indigestion, Cancer, Therapy, Arthralgia, Creatinine, Potassium, Death, Back pain, Cholesterol, Mutation, Menarini, Medical imaging, Pharmaceutical industry

Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, commercializes ORSERDU in the U.S. and E.U.

Key Points: 
  • Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, commercializes ORSERDU in the U.S. and E.U.
  • Under the Sub-Licensing agreement, SciClone will pursue the development and registration of ORSERDU in China and commercialise ORSERDU upon its regulatory approval in China.
  • "Patients living with metastatic breast cancer need effective and tolerable options," said Elcin Barker Ergun, CEO of the Menarini Group.
  • "We are proud to partner with SciClone in an effort to register a new breast cancer treatment for patients in China that can offer efficacy in a once-daily pill."

Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer

Retrieved on: 
Tuesday, November 7, 2023
Neoplasm, Patient, Abdominal pain, Constipation, SOC, Headache, Food, Progression-free survival, Fatigue, European Commission, Vomiting, Diarrhea, PFS, Safety, DSM-IV codes, HIV disease progression rates, Holding, Nausea, Republic, Civil service commission, ESR1, Risk, Triglyceride, MBC, ER, Breast cancer, Anemia, Woman, Oncology, Indigestion, Cancer, Therapy, Arthralgia, Creatinine, Potassium, Death, Back pain, Cholesterol, Mutation, Menarini, Medical imaging, Pharmaceutical industry

Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, commercializes ORSERDU in the U.S. and E.U.

Key Points: 
  • Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, commercializes ORSERDU in the U.S. and E.U.
  • Under the Sub-Licensing agreement, SciClone will pursue the development and registration of ORSERDU in China and commercialise ORSERDU upon its regulatory approval in China.
  • "Patients living with metastatic breast cancer need effective and tolerable options," said Elcin Barker Ergun, CEO of the Menarini Group.
  • "We are proud to partner with SciClone in an effort to register a new breast cancer treatment for patients in China that can offer efficacy in a once-daily pill."

OrsoBio to Present Phase 1 Data for the Liver-Targeted LXR Inverse Agonist TLC-2716 in Development for Severe Hypertriglyceridemia and NASH at AHA’s Scientific Sessions 2023

Retrieved on: 
Monday, November 6, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, C3, Plasma, De novo, LXR, DSM-IV codes, Liver, MD, Safety, Apolipoprotein B, American Heart, Lipid, Oral, NASH, LDL, PK, Liver X receptor, Triglyceride, Liver disease, AE, Patient, Fatty liver disease, Cholesterol, Hypertriglyceridemia, Pharmaceutical industry, Pharmacokinetics, ANGPTL3

TLC-2716 is in clinical development as a potential treatment for severe hypertriglyceridemia (SHTG) and nonalcoholic steatohepatitis (NASH).

Key Points: 
  • TLC-2716 is in clinical development as a potential treatment for severe hypertriglyceridemia (SHTG) and nonalcoholic steatohepatitis (NASH).
  • In data presented at AASLD’s The Liver Meeting®, TLC-2716 demonstrated highly potent and consistent improvements in plasma triglycerides and cholesterol and hepatic steatosis in preclinical models.
  • Notably, due to active hepatic uptake and limited systemic exposures, TLC-2716 did not adversely affect peripheral reverse cholesterol transport.
  • The results support the ongoing development of TLC-2716 in patients with metabolic disorders including SHTG and NASH.